CTKB · Categories · Form 4
CTKB - SEC Form 4 insider transactions
Cytek Biosciences Inc. (CTKB) sec form 4 insider transactions - real-time wire coverage filtered to Form 4 only.
Recent Form 4 for CTKB
- Director Ball Jack converted options into 43,973 shares, increasing direct ownership by 103% to 86,678 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Muir Glenn P4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Chin Richard4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Imper Vera converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Neff Deborah J converted options into 43,973 shares, increasing direct ownership by 280% to 59,679 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 43,973 shares, increasing direct ownership by 263% to 60,694 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 1,454 shares, increasing direct ownership by 10% to 16,721 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 38% to 22,392 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 22,179 shares and covered exercise/tax liability with 5,532 shares, increasing direct ownership by 0.34% to 4,932,580 units (SEC Form 4) (tax withholding)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 10,464 shares and covered exercise/tax liability with 2,685 shares, increasing direct ownership by 22% to 43,466 units (SEC Form 4) (for withholding tax)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 80,062 shares and covered exercise/tax liability with 25,542 shares, increasing direct ownership by 1% to 5,477,203 units (SEC Form 4) to cover taxes4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Chief Financial Officer Mccombe William D. converted options into 25,719 shares and covered exercise/tax liability with 9,229 shares, increasing direct ownership by 17% to 111,177 units (SEC Form 4) (for tax liability)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie covered exercise/tax liability with 8,719 shares and converted options into 24,295 shares, increasing direct ownership by 12% to 150,012 units (SEC Form 4) to satisfy withholding obligation4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming gifted 1,176,000 shares, decreasing direct ownership by 19% to 4,915,933 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 60% to 16,285 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie converted options into 29,722 shares and covered exercise/tax liability with 11,748 shares, increasing direct ownership by 15% to 134,436 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 9,828 shares and covered exercise/tax liability with 3,043 shares, increasing direct ownership by 23% to 35,687 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 83,844 shares and covered exercise/tax liability with 20,988 shares, increasing direct ownership by 1% to 5,422,683 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Chief Financial Officer Mccombe William D. converted options into 23,721 shares and covered exercise/tax liability with 9,748 shares, increasing direct ownership by 17% to 94,687 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 25,400 shares and covered exercise/tax liability with 7,731 shares, increasing direct ownership by 0.29% to 6,091,933 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 2,908 shares, increasing direct ownership by 24% to 15,267 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin covered exercise/tax liability with 1,339 shares and converted options into 4,514 shares, increasing direct ownership by 0.06% to 5,359,827 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming covered exercise/tax liability with 395 shares and converted options into 1,332 shares, increasing direct ownership by 0.02% to 6,074,264 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie converted options into 1,346 shares and covered exercise/tax liability with 525 shares, increasing direct ownership by 0.71% to 116,462 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 21,031 shares and covered exercise/tax liability with 5,123 shares, increasing direct ownership by 0.26% to 6,073,327 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe covered exercise/tax liability with 1,885 shares and converted options into 7,371 shares, increasing direct ownership by 23% to 28,902 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie converted options into 24,307 shares and covered exercise/tax liability with 7,817 shares, increasing direct ownership by 17% to 115,641 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Chief Financial Officer Mccombe William D. covered exercise/tax liability with 6,228 shares and converted options into 19,371 shares, increasing direct ownership by 19% to 80,714 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 69,641 shares and covered exercise/tax liability with 27,406 shares, increasing direct ownership by 0.79% to 5,356,652 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 2,181 shares, increasing direct ownership by 21% to 12,359 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Chin Richard converted options into 6,107 shares, increasing direct ownership by 150% to 10,178 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 21,031 shares and covered exercise/tax liability with 5,738 shares, increasing direct ownership by 0.25% to 6,057,419 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 7,371 shares and covered exercise/tax liability with 2,872 shares, increasing direct ownership by 24% to 23,416 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie covered exercise/tax liability with 8,829 shares and converted options into 24,307 shares, increasing direct ownership by 18% to 99,151 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 69,641 shares and covered exercise/tax liability with 16,959 shares, increasing direct ownership by 1% to 5,314,417 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Chief Financial Officer Mccombe William D. converted options into 19,371 shares and covered exercise/tax liability with 7,546 shares, increasing direct ownership by 21% to 67,571 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 2,181 shares, increasing direct ownership by 27% to 10,178 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Chin Richard converted options into 4,071 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Chin Richard4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Neff Deborah J4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Ball Jack4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Holder Michael4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Director Imper Vera4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Imper Vera converted options into 15,706 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Hardison Don M converted options into 15,706 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Ball Jack converted options into 15,706 shares, increasing direct ownership by 58% to 42,705 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Neff Deborah J converted options into 15,706 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Chief Financial Officer Mccombe William D. converted options into 33,983 shares and covered exercise/tax liability with 13,237 shares (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 48,679 shares and covered exercise/tax liability with 11,855 shares, increasing direct ownership by 0.70% to 5,261,735 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie converted options into 16,876 shares and covered exercise/tax liability with 6,575 shares, increasing direct ownership by 14% to 83,673 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 4,913 shares and covered exercise/tax liability with 1,915 shares, increasing direct ownership by 19% to 18,917 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming covered exercise/tax liability with 4,356 shares and converted options into 14,680 shares, increasing direct ownership by 0.17% to 6,042,126 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 1,454 shares, increasing direct ownership by 22% to 7,997 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF LEGAL OFFICER Barnett Valerie converted options into 15,221 shares and covered exercise/tax liability with 5,929 shares, increasing direct ownership by 15% to 73,372 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SVP, GLOBAL SALES AND SERVICES Busque Philippe converted options into 4,995 shares and covered exercise/tax liability with 1,947 shares, increasing direct ownership by 24% to 15,919 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- PRESIDENT AND CEO Jiang Wenbin converted options into 45,175 shares and covered exercise/tax liability with 12,656 shares, increasing direct ownership by 0.63% to 5,224,911 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- CHIEF TECHNOLOGY OFFICER Yan Ming converted options into 17,183 shares and covered exercise/tax liability with 5,096 shares, increasing direct ownership by 0.20% to 6,031,802 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- Director Holder Michael converted options into 2,908 shares, increasing direct ownership by 80% to 6,543 units (SEC Form 4)4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by CHIEF TECHNOLOGY OFFICER Yan Ming4 - Cytek Biosciences, Inc. (0001831915) (Issuer)
- SEC Form 4 filed by Chief Financial Officer Mccombe William D.4 - Cytek Biosciences, Inc. (0001831915) (Issuer)